GALECTIN THERAPEUTICS INC. Loss Contingency, Estimate of Possible Loss
GALECTIN THERAPEUTICS INC. (GALT) had Loss Contingency, Estimate of Possible Loss of $1.00 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency, Estimate
us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2025-05-15
- 2025-03-31: Loss Contingency, Estimate of Possible Loss $1.00M.
- 2024-12-31: Loss Contingency, Estimate of Possible Loss $1.00M.
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2025-03-31 | $1.00M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.00M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |